FDA’s Adverse Event Reporting Rule Would Generate “Noise,” PhRMA Says
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposed rule on suspected adverse events would generate excess reports without increasing the value of the surveillance, the Pharmaceutical Research & Manufacturers of America says